Press Releases Medigene AG OTC Markets

Equities

MDGEF

DE000A1X3W00

Market Closed - OTC Markets Other stock markets 10:36:56 2024-03-28 EDT			5-day change	1st Jan Change
2.297 ^USD	-11.96%		-5.49%	+53.10%

07-03	Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor in China	CI
06-27	Medigene Presents Efficient 6-Day TCR-T Therapy Production Process with High Stemness	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor in China	07-03	GL
Medigene Presents Efficient 6-Day TCR-T Therapy Production Process with High Stemness	06-27	GL
Medigene Reports Results of Annual General Meeting	06-24	GL
Medigene to Present at the Cell and Gene Therapy In-Depth Focus Summit 2024	06-21	GL
Medigene AG Announces Lead Selection for MDG2021, Expanding TCR-T KRAS Library Targeting Solid Tumors	06-20	GL
Medigene AG Announces Lead Selection for MDG2021, Expanding TCR-T KRAS Library Targeting Solid Tumors	06-20	AQ
Medigene : Expands its End to End Platform by Submitting Three Patents to the European Patent Office	06-19	PU
Medigene : Release according to Article 40, Section 1 of the WpHG	06-19	PU
Medigene AG Expands its End-to-End Platform by Submitting Three Development Optimization Technology Patents to the European Patent Office	05-28	GL
Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announced Term	05-21	GL
Medigene : Description of the remuneration system for Supervisory Board members	05-17	PU
Medigene : Report of the Executive Board on agenda item 8	05-17	PU
Medigene : Report of the Executive Board on agenda item 9	05-17	PU
Medigene : Explanations of the rights of shareholders	05-17	PU
Medigene : Proxy to third person	05-17	PU
Medigene : Data protection information	05-17	PU
Medigene : CV Dr. Gerd Zettlmeissl	05-17	PU
Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS	05-15	GL
Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS	05-15	AQ
Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise	05-14	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Medigene AG OTC Markets

Equities

MDGEF

DE000A1X3W00

Press Releases

Filters